Similarly, other small molecule inhibitors and antibody-drug conjugates are being tested in other types of cancers where the IGF-1R/PI3K and AXL signaling pathways have also recently attracted attention, including in primary bone cancers where they play a major role in oncogenesis, cell differentiation and fate, metastasis, and drug resistance (53). The gene discussed is IGF1R; the disease is cancer.